Many Medicaid enrollees have restricted access to SGLT2 inhibitors, GLP-1 receptor agonists

Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a study published online April 22 in the Annals of Internal Medicine.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup